![](https://investorshub.advfn.com/uicon/665829.png?cb=1539811999)
Wednesday, April 03, 2019 2:45:54 PM
Question: Is 50 clinics too much to expect due to clinics for stem cell treatments on a cash basis just not being in existence?
Answer:
At least 1 other ticker currently trading at a 2-3 X multiple our PPS exists claiming 750+ clinics nationwide still offering their stem cell services profitably despite an active DOJ investigation regarding a possible FDA violation.
Some longs here might then ask what CELZ might look like for MC if suddenly FDA were to identify our CaverStem (and don't forget FemCelz) as the only FDA compliant ED stem cell treatment currently extant. Know what? Forget FDA acknowledgement to some other company... We are contacting doctors directly with our FDA compliant protected IP.
Hmm, 750 clinics, plus our 50 other clinics with no startup, salary, insurance or hardware overhead, etc...
800 clinics at 12 procedures per week = 9,600 procedures per week.
9600 procedures/week at 52 procedures per year = 499,200 procedures per year domestically.
At 499,200 annual procedures yielding $1,600 revenue each we get $798,720,000 PER YEAR.
This could equate to .61 PPS by the end of the year domestically and EXCLUDES any international revenue but includes a 1.3 Billy OS.
If you bought in and averaged .05 PPS last year, I think you were close to what a reasonable minimum short term (but long) expectation could be for this year. As was discussed last July/August on this message board, this ticker has room to run to the .60-.68 PPS range (possibly more depending on International sales that could 2X the high range) with no knowing when that could occur.
IMO, my buy-in PPS averaging around .016 PPS average is money well spent, and this year as I watch PPS rise, I get the year and 1 day capital gains tax break rolling across my last year's stock purchases. This has been my plan. I'm liking what my math IMPLIES / shows me so far.
-Go CELZ$$$$
Recent CELZ News
- Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin • GlobeNewswire Inc. • 06/24/2024 12:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/05/2024 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:02:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:45:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
- Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain • PR Newswire (US) • 10/10/2023 12:00:00 PM
- Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain • PR Newswire (US) • 09/19/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:45:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/29/2023 09:37:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/28/2023 01:00:18 PM
- Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements • PR Newswire (US) • 06/28/2023 12:00:00 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM